- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
17 result(s) found for: Diabetes insipidus.
Displaying page 1 of 1.
EudraCT Number: 2020-002204-38 | Sponsor Protocol Number: NDI-2020 | Start Date*: 2020-11-24 | |||||||||||
Sponsor Name:Claus Bistrup | |||||||||||||
Full Title: Treatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication | |||||||||||||
Medical condition: Nephrogenic diabetes insipidus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001809-24 | Sponsor Protocol Number: JDJW-001 | Start Date*: 2013-07-31 | ||||||||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
Full Title: Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test | ||||||||||||||||||
Medical condition: lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001202-84 | Sponsor Protocol Number: lithium-15-12-06 | Start Date*: 2007-02-01 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders | |||||||||||||
Medical condition: Lithium-induced Nephrogenic Diabetes Insipidus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005970-41 | Sponsor Protocol Number: SDW-001 | Start Date*: 2012-02-27 | ||||||||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
Full Title: The effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study | ||||||||||||||||||
Medical condition: lithium-induced nephrogenic diabetes insipidus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003360-56 | Sponsor Protocol Number: 20050183 | Start Date*: 2009-08-28 | |||||||||||
Sponsor Name:Dept. of Pediatrics, The Childrens Hospital, Denver | |||||||||||||
Full Title: Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. | |||||||||||||
Medical condition: Kongenit nefrogen diabetes insipidus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004159-19 | Sponsor Protocol Number: 2018-00938 | Start Date*: Information not available in EudraCT |
Sponsor Name:University Hospital Basel | ||
Full Title: Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study | ||
Medical condition: Polyuria-polydipsia syndrome (PPS) is divided into the three main entities central (complete or partial) diabetes insipidus (DI), nephrogenic DI and primary polydipsia (PP). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001591-30 | Sponsor Protocol Number: S-20150201 | Start Date*: 2017-11-06 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil | |||||||||||||
Medical condition: Nephrogenic diabetes insipidus because of AVP2R-mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004594-43 | Sponsor Protocol Number: ISTEM02 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:CECS/I-Stem | |||||||||||||
Full Title: AUDIOWOLF: A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation | |||||||||||||
Medical condition: Wolfram syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004943-35 | Sponsor Protocol Number: 5122016 | Start Date*: 2017-03-01 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Stimulation of ADH independent urine concentration in healthy volunteers | ||
Medical condition: healthy volunteers; the information of this pilot study will be used in the care of patients with diabetes insipidus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003600-41 | Sponsor Protocol Number: APHP200042 | Start Date*: 2022-01-25 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: AMIloride for the treatment of Nephrogenic Diabetes insipidus for patients with bipolar disorder treated with lithium: a randomized controlled trial | ||
Medical condition: NA | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003853-70 | Sponsor Protocol Number: PNRR-MR1-2022-12375914 | Start Date*: 2023-05-02 | |||||||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||||||||||||
Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi... | |||||||||||||||||||||||
Medical condition: Wolfram syndrome type 1 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004115-27 | Sponsor Protocol Number: IIBSP-OXI-2020-102 | Start Date*: 2021-05-10 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Identification and clinical relevance of oxytocin deficient status: randomized, crossover, placebo-controlled pathophysiological pilot study: GLP1 study | ||
Medical condition: Hypopituitarism | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000918-38 | Sponsor Protocol Number: C0311002 | Start Date*: 2019-05-16 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROP... | |||||||||||||
Medical condition: Growth Hormone Deficiency in Children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004058-11 | Sponsor Protocol Number: RM-493-023 | Start Date*: Information not available in EudraCT |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström syndrome (AS) Patients with Moderate to Severe Obesity | ||
Medical condition: Obesity and hyperphagia in patients with Bardet-Biedl Syndrome or Alström syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2013-000830-37 | Sponsor Protocol Number: CP-4-005 | Start Date*: 2013-07-03 | |||||||||||
Sponsor Name:OPKO Biologics Ltd. | |||||||||||||
Full Title: A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency | |||||||||||||
Medical condition: Adult or childhood onset growth hormone deficiency (GHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) GR (Completed) GB (Completed) AT (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001699-20 | Sponsor Protocol Number: 042011 | Start Date*: 2012-05-18 |
Sponsor Name:St. Anna Kinderkrebsforschung, GmbH | ||
Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS | ||
Medical condition: Langerhans cell histiocytosis | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004940-27 | Sponsor Protocol Number: AIC316-03-II-01(Phase3) | Start Date*: 2022-01-05 |
Sponsor Name:AiCuris Anti-infective Cures GmbH | ||
Full Title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in ... | ||
Medical condition: Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
